Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BCAX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $560.31M
- EPS (TTM)
- -$3.46
- Dividend yield
- None
- 52-week range
- 7.87 – 30.99
- Day range
- 8.43 – 9.14
- Volume / Avg
- 814.49K / 1.20M
- Beta
- —
- Shares outstanding
- 66.39M
52-week range
BCAX stock today
Shares of Bicara Therapeutics (BCAX) finished lower on Nov 20 at $8.44, a drop of 7.46% or $0.68 per share, versus the S&P 500's 3.70% decline. At this level, BCAX sits near the bottom of its 52-week range of $7.87 to $30.99: 72.8% below the high, set on Jul 7, 2026 and 7.2% above the low. BCAX is down 49.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.2%.
Bicara Therapeutics has posted a net loss over the last twelve months (EPS of -$3.46), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Bicara Therapeutics
Company profileBicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Claire Mazumdar Clemon M.B.A., Ph.D.
- Headquarters
- Boston, MA
- Employees
- 103
- IPO year
- 2024
- Website
- bicara.com
Financial highlights
Full financialsBicara Therapeutics reported a net loss of $137.9 million, compared with a loss of $68.0 million a year earlier. Diluted earnings per share came in at -$2.52.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-137.95M | $-68.00M | $-51.98M |
| EPS (diluted) | $-2.52 | $-4.05 | $-89.61 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$32.17+281.16%
- Strong buy 3
- Buy 10
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-1.04 vs $-0.84
- Surprise
- -23.81%
BCAX news
All BCAX news- Bicara (BCAX) Q3 2026 Earnings Call TranscriptNasdaq
- Bicara Therapeutics GAAP EPS of -$1.04 misses by $0.22Seeking Alpha
- Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ETGlobeNewswire
- Pliant Therapeutics Names David Raben As CMO To Lead PLN-101095 DevelopmentNasdaqAMGN, BCAX, PLRX
Bicara Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GERNGeron Corporation | 0.8707 | -4.63% | $560.94M | vs BCAX |
| ANLAdlai Nortye Group Ltd. ADR | 8.55 | -5.63% | $550.60M | vs BCAX |
| ACRSAclaris Therapeutics Inc. | 3.44 | -1.71% | $545.63M | vs BCAX |
| AVBPArriVent BioPharma Inc. | 10.52 | -6.57% | $544.13M | vs BCAX |
| CBIOCrescent Biopharma Inc. | 13.00 | +0.70% | $543.21M | vs BCAX |
| DSGNDesign Therapeutics Inc. | 9.02 | -3.22% | $577.61M | vs BCAX |
| CLYMClimb Bio Inc. | 9.19 | -0.97% | $539.80M | vs BCAX |
| IMMXImmix Biopharma Inc. | 6.96 | -1.14% | $583.33M | vs BCAX |
Indexes, lists and sector
Bicara Therapeutics stock FAQ
What is Bicara Therapeutics's stock price today?
BCAX last traded at $8.44 as of Nov 20, 4:00 PM EST, down 7.46% on the day. Prices are delayed at least 15 minutes.
Who is Bicara Therapeutics's CEO?
Dr. Claire Mazumdar Clemon M.B.A., Ph.D. is the chief executive officer of Bicara Therapeutics Inc., which has about 103 employees.
What is the BCAX 52-week high?
The 52-week high for BCAX is $30.99 and the 52-week low is $7.87. The stock is currently 72.8% below its high.